Skip to main content
. Author manuscript; available in PMC: 2013 Jun 7.
Published in final edited form as: J Neurochem. 2008 Sep 20;107(5):1236–1247. doi: 10.1111/j.1471-4159.2008.05695.x

Figure 2.

Figure 2

Results of PET studies in Mn-exposed animals and in imaged-controls. Panel A depicts the PET imaging results for amphetamine-induced dopamine release (AMPH-DAR). Panel B represents the PET imaging results for dopamine transporter (DAT). Panel C describes the PET results for D2 dopamine receptor (D2R) (panel C). Values were normalized to baseline (prior to Mn exposure). For each curve for the Mn-exposed animals, data points with letters in common are not statistically significantly different. Mn exposure produced the most dramatic effect on AMPH-DAR, with a 36% decrease relative to baseline measured at Mn-1 and a 51% decrease measured at Mn-2. This change was not observed in the imaged-controls. Dopamine transporter levels also decreased throughout the dosing period, with a 19.5% decrease observed at Mn-1 and a 24.5% decrease observed at Mn-2. However, these changes tracked with the decreases observed in the imaged-controls, suggesting that the AMPH administered in the PET studies is responsible for the observed decreases in DAT. A decline in D2R of 14.5% reached statistical significance in the Mn-exposed animals by Mn-2.